Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus

Journal of Viral Hepatitis

Volumn 17, Issue 2, 2010, Pages 123-129

  Tamori, A ^a   Enomoto, M ^a   Kobayashi, S ^a   Iwai, S ^a   Morikawa, H ^a   Sakaguchi, H ^a   Habu, D ^b   Shiomi, S ^a   Imanishi, Y ^a   Kawada, N ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Osaka Prefecture University   (Japan)

Author keywords

Adefovir dipivoxil; Fanconi syndrome; Hepatitis B virus; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CREATININE; LAMIVUDINE; PHOSPHATE; VIRUS DNA;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FANCONI RENOTUBULAR SYNDROME; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; KIDNEY DISEASE; LIVER CIRRHOSIS; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REMISSION;

ADENINE; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CREATININE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FANCONI SYNDROME; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; KIDNEY; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHONIC ACIDS; RENAL INSUFFICIENCY; SERUM; TREATMENT OUTCOME; VIRAL LOAD;

EID: 74049135616     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01160.x     Document Type: Article

References (22)

1. Ganem D. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004 350 : 1118 1129.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004 39 : 857 861.
3. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008 359 : 1486 1500.
4. Lai CL. A one-year trial lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998 339 : 61 68.
5. Chen CH. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004 41 : 454 461.
6. Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004 126 : 91 101.
7. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004 48 : 3498 3507.
8. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007 45 : 307 313.
9. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007 133 : 1445 1451.
10. Yatsuji H, Suzuki F, Sezaki H et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008 48 : 923 931.
11. Izzedine H, Hulot JS, Launay-Vacher V et al. Adefovir Dipivoxil International 437 Study Group; Adefovir Dipivoxil International 438 Study Group. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004 66 : 1153 1158.
12. Usuda S, Okamoto H, Tanaka T et al. Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. J Virol Methods 1999 80 : 97 112.
13. Ide T, Kumashiro R, Toyoda N, Matsuyama K, Miura T, Sata M. Second generation amplicor-HCV monitor assay: clinical features and predictors of the response to interferon. Hepatol Res 2000 18 : 230 238.
14. Gerken G, Gomes J, Lampertico P et al. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods 1998 74 : 155 165.
15. Chevaliez S, Bouvier-Alias M, Laperche S, Pawlotsky JM. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 2008 46 : 1716 1723.
16. Stuyver L, Van Geyt C, De Gendt S et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000 38 : 702 707.
17. Chantrel F, Enache I, Bouiller M et al. Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transpl 1999 14 : 129 136.
18. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008 48 : 750 758.
19. van Bömmel F, Zöllner B, Sarrazin C et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006 44 : 318 325.
20. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008 6 : 1315 1341.
21. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008 359 : 2442 2455.
22. Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002 40 : 1331 1333.